The dawn of the new age that got much anticipated has since arrived, all thanks to the one and only Clay Siegall. For many years, Mr. Clay has been on the forefront helping fight cancer with all the ‘tactical weapons’ at his disposal. With his Ph.D. in Genetics from the George Washington University and a BS in Zoology from the University of Maryland, Siegall is the mastermind behind the creation of Seattle Genetics, an organization that has been in existence since 1998. Apart from playing Co-Founder, Clay Siegall has assumed the active role of CEO and Chairman of Seattle Genetics, with his primary responsibility being to enable the Institute to come up with different antibody-based cancer therapies favorable to cancer patients.
Before 1998, Clay’s life was one filled with activity. Siegall used to work for organizations like the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, a platform that gave Clay the opportunity to learn all that regards to cancer therapy and treatment. As of now, Clay Siegall not only spends his time and energy at Seattle Genetics but also works for Alder BioPharmaceuticals, Mirna Therapeutics, Ultragenyx, and the Fred Hutchinson Cancer Research Center in different capacities. In his tenure as a member of the Board of Directors at Ultragenyx Pharmaceutical Inc., Clay has helped the corporation advance its clinical programs in its fight against rare and ultra-rare diseases.
At the moment, Clay Siegall’s Seattle Genetics is the most dominant biotech firm in the region, a reputation that has not come easy. For years, Seattle Genetics has been testing out its drugs by administering them on human antibodies, hence the tremendous achievements in fighting cancer. Lately, Seattle Genetics has created one powerful antibody that has the potential of fighting cancerous cells with a lot of success. If at all the antibody from Seattle Genetics proves to be effective, then the biopharmaceutical company’s reputation might catapult for a job well done.
Today, Seattle Genetics has grown its assets to more than $10 billion and is an employer to 900 employees, all coming from different regions and backgrounds. Since the beginning, Seattle Genetics has invested a lot in cancer research, something that has now started to bear fruit. If at all everything goes as planned, Seattle Genetics will add 200 more employees to its active roster. Due to Seattle’s’ steep growth, Clay Siegall is making plans to see to it that the Institute markets its drugs on international markets. Thus, it takes a real man to build a company, but a unique type of leader to manage a successful business.